Armistice Capital, LLC 13D and 13G filings for Supernus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 5:20 pm Sale |
2024-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 4,836,000 8.760% |
-260,000 (-5.10%) |
Filing |
| 2024-11-14 5:14 pm Purchase |
2024-09-30 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 5,096,000 9.250% |
446,000 (+9.59%) |
Filing |
| 2024-02-14 2:33 pm Purchase |
2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 4,650,000 8.510% |
294,000 (+6.75%) |
Filing |
| 2023-02-14 1:33 pm Purchase |
2022-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 4,356,000 8.060% |
220,000 (+5.32%) |
Filing |
| 2022-02-14 7:03 pm Purchase |
2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 4,136,000 7.800% |
1,016,000 (+32.56%) |
Filing |
| 2021-02-16 5:00 pm Purchase |
2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 3,120,000 5.900% |
232,000 (+8.03%) |
Filing |